S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Real Problem With "Made in America" Lithium (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Real Problem With "Made in America" Lithium (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Real Problem With "Made in America" Lithium (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Real Problem With "Made in America" Lithium (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Forecast, Price & News

$1.09
+0.09 (+9.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$0.99
▼
$1.09
50-Day Range
$0.60
▼
$1.11
52-Week Range
$0.55
▼
$7.60
Volume
134,191 shs
Average Volume
135,294 shs
Market Capitalization
$11.90 million
P/E Ratio
0.16
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
7.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.58mentions of AcelRx Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.67) to ($2.00) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

917th out of 1,980 stocks

Pharmaceutical Preparations Industry

443rd out of 978 stocks

See Top Rated MarketRank™ Stocks Here

ACRX stock logo

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

May 31, 2023 | americanbankingnews.com
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Short Interest Update
May 30, 2023 | americanbankingnews.com
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Sees Significant Drop in Short Interest
June 2, 2023 | Edge On The Street (Ad)
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
May 17, 2023 | americanbankingnews.com
AcelRx Pharmaceuticals, Inc. to Post Q2 2023 Earnings of ($0.53) Per Share, HC Wainwright Forecasts (NASDAQ:ACRX)
May 13, 2023 | finanznachrichten.de
AcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 12, 2023 | americanbankingnews.com
AcelRx Pharmaceuticals (NASDAQ:ACRX) Rating Lowered to Sell at StockNews.com
May 11, 2023 | msn.com
Recap: AcelRx Pharmaceuticals Q1 Earnings
May 10, 2023 | finance.yahoo.com
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
June 2, 2023 | Edge On The Street (Ad)
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
May 10, 2023 | finance.yahoo.com
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 | americanbankingnews.com
AcelRx Pharmaceuticals (ACRX) to Release Earnings on Wednesday
May 4, 2023 | finance.yahoo.com
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline
May 3, 2023 | msn.com
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
April 27, 2023 | finance.yahoo.com
AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023
April 19, 2023 | americanbankingnews.com
Short Interest in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Expands By 17.5%
April 8, 2023 | americanbankingnews.com
AcelRx Pharmaceuticals (NASDAQ:ACRX) Upgraded by StockNews.com to Hold
April 5, 2023 | finance.yahoo.com
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
April 4, 2023 | finance.yahoo.com
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript
March 31, 2023 | finanznachrichten.de
AcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
March 31, 2023 | markets.businessinsider.com
Acelrx (ACRX) Receives a Hold from H.C. Wainwright
March 30, 2023 | finance.yahoo.com
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
March 29, 2023 | msn.com
Earnings Outlook For AcelRx Pharmaceuticals
March 29, 2023 | americanbankingnews.com
AcelRx Pharmaceuticals (ACRX) Set to Announce Earnings on Thursday
March 21, 2023 | finance.yahoo.com
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
March 14, 2023 | marketwatch.com
AcelRx Pharmaceuticals Shares Rise Premarket on Dsuvia Sale >ACRX
March 14, 2023 | msn.com
AcelRx adds 16% on plans to divest pain therapy
March 14, 2023 | finance.yahoo.com
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
See More Headlines

ACRX Price History

ACRX Company Calendar

Last Earnings
3/30/2023
Today
6/02/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
CUSIP
N/A
CIK
1427925
Web
www.acelrx.com
Phone
(650) 216-3500
Fax
650-216-6500
Employees
43
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$6.91
Trailing P/E Ratio
0.16
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$47.76 million
Net Margins
2,696.50%
Pretax Margin
3,946.35%
Return on Equity
-93.99%
Return on Assets
-50.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.83
Quick Ratio
1.83

Sales & Book Value

Annual Sales
$1.77 million
Price / Sales
6.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.30 per share
Price / Book
0.84

Miscellaneous

Outstanding Shares
10,920,000
Free Float
10,312,000
Market Cap
$11.90 million
Optionable
Optionable
Beta
0.25

Key Executives

  • Vincent J. Angotti
    President, Chief Executive Officer & Director
  • Raffi Asadorian
    Chief Financial & Accounting Officer
  • Pamela Pierce Palmer
    Director & Chief Medical Officer
  • Badri N. Dasu
    Chief Engineering Officer
  • Mark A. Evashenk
    Vice President-Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ACRX Stock - Frequently Asked Questions

How have ACRX shares performed in 2023?

AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 51.8% and is now trading at $1.09.
View the best growth stocks for 2023 here.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 765,800 shares, a drop of 10.5% from the April 30th total of 855,800 shares. Based on an average trading volume of 204,900 shares, the days-to-cover ratio is currently 3.7 days. Approximately 7.1% of the company's shares are sold short.
View AcelRx Pharmaceuticals' Short Interest.

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ACRX earnings forecast.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings data on Thursday, March, 30th. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.90. AcelRx Pharmaceuticals had a net margin of 2,696.50% and a negative trailing twelve-month return on equity of 93.99%.

When did AcelRx Pharmaceuticals' stock split?

AcelRx Pharmaceuticals's stock reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.37%), Simplex Trading LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Adrian Adams and Vincent J Angotti.
View institutional ownership trends.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.09.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $11.90 million and generates $1.77 million in revenue each year. The specialty pharmaceutical company earns $47.76 million in net income (profit) each year or $6.91 on an earnings per share basis.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -